Recent Report on Potassium Voltage Gated Channel Subfamily A Member 5Voltage Gated Potassium Channel Subunit Kv1.5-Pipeline Review, H1 2016

Potassium Voltage Gated Channel Subfamily A Member 5Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5-Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics development and features dormant and discontinued projects.

To view the table of contents and know more details please visit Potassium Voltage Gated Channel Subfamily A Member 5Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5)
- The report assesses Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily A Member 5 (Voltage Gated Potassium Channel Subunit Kv1.5 or KCNA5) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

AstraZeneca Plc Bristol-Myers Squibb Company Laboratoires Pierre Fabre SA Xention Limited

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###